Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurochem Gets FDA Priority Review For AA Amyloidosis Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Filing for Fibrillex in Europe awaits accelerated orphan drug pathway, but could come in fall 2006.

You may also be interested in...



Neurochem Gets Second FDA “Approvable” Letter For Kiacta

FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.

Neurochem Gets Second FDA “Approvable” Letter For Kiacta

FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.

J&J/Neurochem Kiacta Is “Approvable” For Secondary Amyloidosis

Firms plan to submit response based on existing studies in four to six weeks.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel